BRPI0818323A2 - composição farmacêutica, uso de uma composição farmacêutica, e, método para tratar câncer. - Google Patents

composição farmacêutica, uso de uma composição farmacêutica, e, método para tratar câncer.

Info

Publication number
BRPI0818323A2
BRPI0818323A2 BRPI0818323A BRPI0818323A BRPI0818323A2 BR PI0818323 A2 BRPI0818323 A2 BR PI0818323A2 BR PI0818323 A BRPI0818323 A BR PI0818323A BR PI0818323 A BRPI0818323 A BR PI0818323A BR PI0818323 A2 BRPI0818323 A2 BR PI0818323A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
treating cancer
cancer
treating
pharmaceutical
Prior art date
Application number
BRPI0818323A
Other languages
English (en)
Inventor
John Day Andrew
David Blyth John
James Lennon Kieran
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40534840&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0818323(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BRPI0818323A2 publication Critical patent/BRPI0818323A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0818323A 2007-10-12 2008-10-09 composição farmacêutica, uso de uma composição farmacêutica, e, método para tratar câncer. BRPI0818323A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97973607P 2007-10-12 2007-10-12
US8911808P 2008-08-15 2008-08-15
PCT/GB2008/050928 WO2009047565A2 (en) 2007-10-12 2008-10-09 Composition 064

Publications (1)

Publication Number Publication Date
BRPI0818323A2 true BRPI0818323A2 (pt) 2017-05-16

Family

ID=40534840

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0818323A BRPI0818323A2 (pt) 2007-10-12 2008-10-09 composição farmacêutica, uso de uma composição farmacêutica, e, método para tratar câncer.

Country Status (35)

Country Link
US (2) US8168221B2 (pt)
EP (2) EP2433620A1 (pt)
JP (1) JP2011500548A (pt)
KR (1) KR20100099113A (pt)
CN (1) CN101896210A (pt)
AR (1) AR068845A1 (pt)
AT (1) ATE536893T1 (pt)
AU (1) AU2008309385B2 (pt)
BR (1) BRPI0818323A2 (pt)
CA (1) CA2701385A1 (pt)
CL (1) CL2008003022A1 (pt)
CO (1) CO6270344A2 (pt)
CR (1) CR11363A (pt)
CU (1) CU20100064A7 (pt)
CY (1) CY1112433T1 (pt)
DK (1) DK2209501T3 (pt)
DO (1) DOP2010000105A (pt)
EA (1) EA201000545A1 (pt)
ES (1) ES2377426T3 (pt)
HK (1) HK1143095A1 (pt)
HR (1) HRP20120085T1 (pt)
IL (1) IL204953A0 (pt)
MX (1) MX2010003989A (pt)
NI (1) NI201000052A (pt)
NZ (1) NZ585310A (pt)
PE (1) PE20091032A1 (pt)
PL (1) PL2209501T3 (pt)
PT (1) PT2209501E (pt)
SG (1) SG182138A1 (pt)
SI (1) SI2209501T1 (pt)
SV (1) SV2010003529A (pt)
TW (1) TW200924768A (pt)
UY (1) UY31385A1 (pt)
WO (1) WO2009047565A2 (pt)
ZA (1) ZA201002477B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1816527A (zh) 2003-06-06 2006-08-09 菲布罗根有限公司 含氮杂芳基化合物及其在增加内源性促红细胞生成素中的用途
JP2011500548A (ja) 2007-10-12 2011-01-06 アストラゼネカ アクチボラグ マンニトールおよび／または微結晶性セルロースを含むジボテンタン組成物
CN101822796B (zh) * 2010-03-17 2012-01-04 山西仟源制药有限公司 一种银冰含片及制备方法和应用
WO2011143347A2 (en) * 2010-05-11 2011-11-17 Sensient Colors Llc Film coating composition and methods of making and using the same
JO3753B1 (ar) 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه
EP2844234B1 (de) * 2012-04-27 2020-01-08 Merck Patent GmbH Tabletten mit überzug und deren herstellung
DK2872488T3 (en) 2012-07-16 2018-10-29 Fibrogen Inc CRYSTALLINIC FORMS OF A PROLYL HYDROXYLASE INHIBITOR
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
CN110448537A (zh) * 2013-06-06 2019-11-15 菲布罗根有限公司 Hif羟化酶抑制剂的药物制剂
CA3174773A1 (en) * 2020-03-31 2021-10-07 Eisai R&D Management Co., Ltd. Tablet, medicine, methods for producing these, and kit

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3674794A (en) * 1970-03-18 1972-07-04 Ciba Geigy Corp Certain-3-pyridine-sulfonamide derivatives
UA58494C2 (uk) * 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
US5783705A (en) * 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
ATE292129T1 (de) * 1997-04-28 2005-04-15 Encysive Pharmaceuticals Inc Sulfonamide für die behandlung von störungen durch endothelin vermittelt
WO2000078292A1 (fr) * 1999-06-18 2000-12-28 Takeda Chemical Industries, Ltd. Preparations solides a desintegration rapide
JP2001058944A (ja) * 1999-06-18 2001-03-06 Takeda Chem Ind Ltd 速崩壊性固形製剤
EP1446118B1 (en) 2001-11-13 2008-01-09 Pharmacia Corporation Oral dosage form of parecoxib
GB0219660D0 (en) * 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
US20060030581A1 (en) * 2002-09-20 2006-02-09 Debusi Laura A Mannitol formulation for integrin receptor antagonist
GB0223854D0 (en) * 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
GB0320806D0 (en) 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
US7772232B2 (en) 2004-04-15 2010-08-10 Bristol-Myers Squibb Company Quinazolinyl compounds as inhibitors of potassium channel function
GB0425854D0 (en) 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
CN101032464A (zh) * 2007-04-01 2007-09-12 杨喜鸿 含有利莫那班和聚乙烯吡咯烷酮的组合物、固体分散体及其制备和药物应用
JP2011500548A (ja) 2007-10-12 2011-01-06 アストラゼネカ アクチボラグ マンニトールおよび／または微結晶性セルロースを含むジボテンタン組成物

Also Published As

Publication number Publication date
SG182138A1 (en) 2012-07-30
HK1143095A1 (en) 2010-12-24
CU20100064A7 (es) 2011-10-05
ZA201002477B (en) 2010-12-29
ATE536893T1 (de) 2011-12-15
HRP20120085T1 (hr) 2012-02-29
AU2008309385A1 (en) 2009-04-16
EP2433620A1 (en) 2012-03-28
NZ585310A (en) 2012-02-24
SV2010003529A (es) 2010-09-13
CO6270344A2 (es) 2011-04-20
US20090099203A1 (en) 2009-04-16
EA201000545A1 (ru) 2010-10-29
EP2209501A2 (en) 2010-07-28
WO2009047565A3 (en) 2009-11-26
UY31385A1 (es) 2009-05-29
MX2010003989A (es) 2010-04-27
ES2377426T3 (es) 2012-03-27
US20120177705A1 (en) 2012-07-12
CN101896210A (zh) 2010-11-24
AU2008309385B2 (en) 2011-10-20
DK2209501T3 (da) 2012-02-27
WO2009047565A2 (en) 2009-04-16
NI201000052A (es) 2011-03-24
KR20100099113A (ko) 2010-09-10
CA2701385A1 (en) 2009-04-16
AR068845A1 (es) 2009-12-09
TW200924768A (en) 2009-06-16
CR11363A (es) 2010-07-14
PE20091032A1 (es) 2009-08-15
PL2209501T3 (pl) 2012-03-30
DOP2010000105A (es) 2010-08-15
JP2011500548A (ja) 2011-01-06
PT2209501E (pt) 2012-02-03
US8168221B2 (en) 2012-05-01
CY1112433T1 (el) 2015-12-09
EP2209501B1 (en) 2011-12-14
SI2209501T1 (sl) 2012-03-30
IL204953A0 (en) 2010-11-30
CL2008003022A1 (es) 2010-07-23

Similar Documents

Publication Publication Date Title
BRPI0922475A2 (pt) composto, composição farmacêutica , método para tratar câncer, e, uso de um composto.
BRPI0818426A2 (pt) produto de combinação, uso de um produto de combinação, e, método para tratar câncer
BRPI0811589A2 (pt) Composição farmacêutica e método para tratar câncer
BRPI0818323A2 (pt) composição farmacêutica, uso de uma composição farmacêutica, e, método para tratar câncer.
BRPI0819218A2 (pt) Métodos, estojos e composições para administração de compostos farmacêuticos
BRPI0912539A2 (pt) composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
BRPI0818244A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença
BRPI0811059A2 (pt) combinação, composição farmacêutica, método para tratar câncer em um animal de sangue quente, e, uso de uma combinação
BR112012018951A2 (pt) composição farmacêutica, combinação farmacêutica e método para o tratamento e\ou prevenção de um câncer e anticorpo
BRPI0813237A2 (pt) Composto, método para preparar o composto, composição, medicamento, e, uso do composto.
BRPI0815057A2 (pt) Composto, composição farmacêutica, e, método para tratar infecção.
BRPI0813311A2 (pt) Composto, métodos para modulara a atividade de uma proteína quinase e para tratar câncer em um indivíduo, e, composição farmacêutica.
CL2007003226A1 (es) Compuestos derivados de piridinona; composicion farmaceutica; y uso para tratar el cancer.
BRPI0815387A2 (pt) composição farmacêutica, método para fazer uma composição farmacêutica e método de tratar uma condição
BRPI0819755A2 (pt) composto, composição farmacêutica, processos para a preparação de um composto e de uma composição farmacêutica, uso de um composto, e, método para tratar ou reduzir o risco de uma doença ou uma condição inflamatória
BRPI0911685A2 (pt) composto, método para o tratamento de uma doença, uso de um composto, composição farmacêutica, e, kit
BRPI0917705A2 (pt) composto, pró-droga, composição farmacêutica, método para tratar ou prevenir uma doença ou condição, e, uso do composto
BRPI1013984A2 (pt) composto , composição farmacêutica, método para tratamento ou profilaxia de uma doença ou condição, e, uso de um composto.
BRPI0720546A2 (pt) Composto, inibidor, medicamento, agente antitumor, composição farmacêutica, método para tratar câncer, e, uso do composto
BRPI0907977A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BRPI0814503A2 (pt) composto, uso de um composto, métodos para produzir um efeito anti-proliferativo em um animal de sangue quente, e para tratar uma doença, e, composição farmacêutica
BRPI0819799A2 (pt) Composto, intermediário, uso de um composto, composição farmacêutica, e, método para prevenir, tratar ou melhorar uma doença
BRPI0816097A2 (pt) composição farmacêutica, método para tratar eritema em um paciente com rosácea, e, uso de uma composição.
BRPI0815591A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratar uma doença, condição ou distúrbio.
BRPI0907974A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]